01 — What is it?
Dual GIP and GLP-1 receptor agonist with extensive Phase 3 evidence in type 2 diabetes and obesity. Approved products exist for specific indications.
Database / Research Profiles / Tirzepatide
RESEARCH PROFILE
TIRZEPATIDE
GIP/GLP-1 receptor agonist
MetabolicStrong human clinical evidence
EVIDENCE SNAPSHOTSTRONG HUMAN CLINICAL EVIDENCE
Large randomized human evidence base; gastrointestinal effects are common in trials.
Research-first: This profile summarizes published evidence and regulatory context. It is educational reference material, not a diagnosis, treatment recommendation, or personalized dosing protocol.
02 — Research category
Metabolic. Evidence strength is based on the availability and quality of human clinical data, not on popularity in the research-peptide market.
03 — Evidence map
Human evidence: YESPreclinical evidence: SUPPLEMENTALPersonal dosing protocol: NOT PROVIDED
Large randomized human evidence base; gastrointestinal effects are common in trials.
04 — Mechanism / biology
Dual GIP and GLP-1 receptor agonist with extensive Phase 3 evidence in type 2 diabetes and obesity. Approved products exist for specific indications.
05 — Safety & limitations
Safety depends on the exact molecule, formulation, route, dose, indication and study population. Research-market products may differ in identity, purity, sterility or stability from materials used in published trials. Absence of reported adverse events in a small study does not establish long-term safety.
06 — Regulatory context
Regulatory status varies by compound and jurisdiction. Where an approved product exists, its approval applies only to specified formulations and indications. Investigational or research-market status should not be presented as equivalent to approval.